Duncan Rudkin, Chief Executive of the GPhC said:
“Further to our recent statement on Avastin, we wanted to highlight to pharmacy professionals that the pharmaceutical companies, Bayer and Novartis, applied to the High Court for permission to appeal the outcome of the case and this was refused on 26 October 2018. We understand the companies now intend to apply to the Court of Appeal for permission to appeal. We will be following the application closely and carefully considering the outcome.
“Meanwhile, the issues raised by the case are complex and pharmacy professionals affected by the judgment should think carefully about getting relevant governance and legal advice.”